A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants
Status:
Recruiting
Trial end date:
2023-09-29
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in
participants with AD (part A) and healthy participants who are of first-generation Japanese
origin (part B). The study will also investigate how much LY3372993 gets into the bloodstream
and will test the effects of LY3372993. Participation could last up to about 61 weeks and may
include up to 28 visits to the study center.